Literature DB >> 16966442

Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines.

M Brunelle1, E A Sartin, L G Wolfe, J Sirois, M Doré.   

Abstract

Mammary cancer is the most common cancer in female dogs. Induction of cyclooxygenase-2 (COX-2), a key enzyme in prostaglandins (PGs) biosynthesis, has been demonstrated in various cancers in humans and dogs, including mammary cancer. The objective of this study was to investigate the expression and regulation of COX-2 in canine mammary epithelial cells. Cell lines derived from normal and neoplastic canine mammary glands were cultured in the absence or presence of phorbol 12-myristate 13-acetate (PMA), and immunoblots, immunocytochemistry, radioimmunoassays, and a cell proliferation assay were used to study COX-2 expression and PGs production. Results showed that the neoplastic cell line CMT12 constitutively overexpressed COX-2 protein whereas other mammary cell lines expressed low to undetectable basal levels of COX-2 protein. Basal PGE(2) production was significantly higher (P < .05) in CMT12 compared to other cell lines. Levels of COX-2 protein in CMT12 decreased in a time-dependent manner with serum starvation, and PMA stimulation induced a strong time-dependent increase in COX-2 protein. Treatment of CMT12 cells with NS-398 (a specific COX-2 inhibitor) significantly blocked PGE(2) synthesis and reduced cell proliferation (P < .05). These results indicate that some neoplastic canine mammary cell lines constitutively overexpress COX-2, and that COX-2 inhibition decreases PGE(2) production and cell proliferation, supporting a role for COX-2 and PGs in canine mammary oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966442     DOI: 10.1354/vp.43-5-656

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  9 in total

1.  Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.

Authors:  Carlos H de M Souza; Evandro Toledo-Piza; Renee Amorin; Andrigo Barboza; Karen M Tobias
Journal:  Can Vet J       Date:  2009-05       Impact factor: 1.008

2.  Expression and significance of PTEN and VEGF in canine mammary gland tumours.

Authors:  C W Qiu; D G Lin; J Q Wang; C Y Li; G Z Deng
Journal:  Vet Res Commun       Date:  2008-05-07       Impact factor: 2.459

3.  Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells.

Authors:  María P Iturriaga; Rodolfo Paredes; Jose I Arias; Cristian G Torres
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

4.  4,5-Diaryl 3(2H)Furanones: Anti-Inflammatory Activity and Influence on Cancer Growth.

Authors:  Dmitrii Semenok; Jury Medvedev; Lefki-P Giassafaki; Iason Lavdas; Ioannis S Vizirianakis; Phaedra Eleftheriou; Antonis Gavalas; Anthi Petrou; Athina Geronikaki
Journal:  Molecules       Date:  2019-05-06       Impact factor: 4.411

Review 5.  Current biomarkers of canine mammary tumors.

Authors:  Ilona Kaszak; Anna Ruszczak; Szymon Kanafa; Kamil Kacprzak; Magdalena Król; Piotr Jurka
Journal:  Acta Vet Scand       Date:  2018-10-29       Impact factor: 1.695

6.  Expression and significance of CHIP in canine mammary gland tumors.

Authors:  Huanan Wang; Xu Yang; Yipeng Jin; Shimin Pei; Di Zhang; Wen Ma; Jian Huang; Hengbin Qiu; Xinke Zhang; Qiuyue Jiang; Weidong Sun; Hong Zhang; Degui Lin
Journal:  J Vet Med Sci       Date:  2015-07-09       Impact factor: 1.267

7.  Diagnosis, classification and grading of canine mammary tumours as a model to study human breast cancer: an Clinico-Cytohistopathological study with environmental factors influencing public health and medicine.

Authors:  Radmehr Shafiee; Javad Javanbakht; Nahid Atyabi; Pegah Kheradmand; Danial Kheradmand; Alimohammad Bahrami; Hasti Daraei; Farshid Khadivar
Journal:  Cancer Cell Int       Date:  2013-08-09       Impact factor: 5.722

Review 8.  In vitro comparative models for canine and human breast cancers.

Authors:  Simona Visan; Ovidiu Balacescu; Ioana Berindan-Neagoe; Cornel Catoi
Journal:  Clujul Med       Date:  2016-01-15

9.  The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro.

Authors:  Lisa Y Pang; Sally A Argyle; Ayako Kamida; Katherine O'Neill Morrison; David J Argyle
Journal:  BMC Vet Res       Date:  2014-09-05       Impact factor: 2.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.